Release Date: 01/06/18 09:55 Summary: Supplementary Target's Statement Price Sensitive: Yes Download Document 6.42MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%